
    
      This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects
      who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups, RAB
      ER 50 mg (once daily) or Ranitidine 150 mg (twice daily).
    
  